
## James C Cloyd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4123066/publications.pdf Version: 2024-02-01



LAMES C CLOVD

#	Article	IF	CITATIONS
1	Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. New England Journal of Medicine, 2019, 381, 2103-2113.	27.0	342
2	A Comparison of Rectal Diazepam Gel and Placebo for Acute Repetitive Seizures. New England Journal of Medicine, 1998, 338, 1869-1875.	27.0	262
3	N-acetylcysteine Boosts Brain and Blood Clutathione in Gaucher and Parkinson Diseases. Clinical Neuropharmacology, 2013, 36, 103-106.	0.7	165
4	Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet, The, 2020, 395, 1217-1224.	13.7	143
5	A review of intranasal formulations for the treatment of seizure emergencies. Journal of Controlled Release, 2016, 237, 147-159.	9.9	117
6	Repeatedâ€Dose Oral Nâ€Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress. Journal of Clinical Pharmacology, 2018, 58, 158-167.	2.0	109
7	A Single-Blind, Crossover Comparison of the Pharmacokinetics and Cognitive Effects of a New Diazepam Rectal Gel with Intravenous Diazepam. Epilepsia, 1998, 39, 520-526.	5.1	78
8	Canine status epilepticus: Proof of principle studies. Epilepsia, 2009, 50, 14-15.	5.1	73
9	A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Research, 2013, 105, 362-367.	1.6	60
10	Relative Bioavailability of Rectally Administered Carbamazepine Suspension in Humans. Epilepsia, 1985, 26, 429-433.	5.1	50
11	Rescue therapies for seizure emergencies: New modes of administration. Epilepsia, 2018, 59, 207-215.	5.1	44
12	Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial. Academic Emergency Medicine, 2019, 26, 940-943.	1.8	39
13	Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. Epilepsia, 2021, 62, 795-806.	5.1	39
14	Bioavailability of Intranasal vs. Rectal Diazepam. Epilepsy Research, 2013, 103, 254-261.	1.6	37
15	Feasibility study of a caregiver seizure alert system in canine epilepsy. Epilepsy Research, 2013, 106, 456-460.	1.6	34
16	Intravenous topiramate: Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia, 2013, 54, 1099-1105.	5.1	31
17	Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia, 2021, 62, 846-856.	5.1	30
18	Failure of Absorption of Gabapentin After Rectal Administration. Epilepsia, 1997, 38, 1242-1244.	5.1	28

JAMES C CLOYD

#	Article	IF	CITATIONS
19	Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease—A Pilot Study. Journal of Clinical Pharmacology, 2020, 60, 744-750.	2.0	25
20	Intravenous topiramate: Safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia, 2013, 54, 1106-1111.	5.1	24
21	Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy. CNS Drugs, 2015, 29, 1009-1022.	5.9	24
22	Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. Epilepsy Research, 2009, 84, 120-126.	1.6	23
23	A Pilot Study Assessing Pharmacokinetics and Tolerability of Oral and Intravenous Baclofen in Healthy Adult Volunteers. Journal of Child Neurology, 2015, 30, 37-41.	1.4	23
24	The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases. Clinical Pharmacology and Therapeutics, 2012, 92, 193-202.	4.7	22
25	Development of benzodiazepines for out-of-hospital management of seizure emergencies. Neurology: Clinical Practice, 2015, 5, 80-85.	1.6	20
26	Canine status epilepticus treated with fosphenytoin: A proof of principle study. Epilepsia, 2015, 56, 882-887.	5.1	17
27	Relative bioavailability of topiramate administered rectally. Epilepsy Research, 2003, 54, 91-96.	1.6	16
28	USL255 extendedâ€release topiramate: Doseâ€proportional pharmacokinetics and tolerability in healthy volunteers. Epilepsia, 2014, 55, 1069-1076.	5.1	15
29	A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. PM and R, 2017, 9, 743-750.	1.6	14
30	Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. Epilepsia, 2015, 56, 915-923.	5.1	13
31	Mechanisms of Antioxidant Induction with High-Dose N-Acetylcysteine in Childhood Cerebral Adrenoleukodystrophy. CNS Drugs, 2015, 29, 1041-1047.	5.9	13
32	N-Acetylcysteine Reverses the Mitochondrial Dysfunction Induced by Very Long-Chain Fatty Acids in Murine Oligodendrocyte Model of Adrenoleukodystrophy. Biomedicines, 2021, 9, 1826.	3.2	13
33	Pharmacologic Considerations in the Treatment of Repetitive or Prolonged Seizures. Journal of Child Neurology, 2007, 22, 47S-52S.	1.4	11
34	Water-soluble benzodiazepine prodrug/enzyme combinations for intranasal rescue therapies. Epilepsy and Behavior, 2015, 49, 347-350.	1.7	11
35	Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy. Frontiers in Veterinary Science, 2016, 3, 107.	2.2	11
36	A modelâ€based approach to assess the exposure–response relationship of Lorenzo's oil in adrenoleukodystrophy. British Journal of Clinical Pharmacology, 2016, 81, 1058-1066.	2.4	11

JAMES C CLOYD

#	Article	IF	CITATIONS
37	GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies. Molecular Genetics and Metabolism, 2020, 129, 35-46.	1.1	11
38	Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson's Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T. Metabolites, 2021, 11, 145.	2.9	11
39	A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil. Journal of Biopharmaceutical Statistics, 2016, 26, 1025-1039.	0.8	10
40	N-acetylcysteine Provides Cytoprotection in Murine Oligodendrocytes through Heme Oxygenase-1 Activity. Biomedicines, 2020, 8, 240.	3.2	10
41	Patients with Gaucher disease display systemic oxidative stress dependent on therapy status. Molecular Genetics and Metabolism Reports, 2020, 25, 100667.	1.1	9
42	Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary studyâ€. Journal of Pharmacy and Pharmacology, 2014, 66, 935-942.	2.4	8
43	Intravenous carbamazepine as shortâ€ŧerm replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two openâ€ŀabel trials. Epilepsia, 2015, 56, 906-914.	5.1	8
44	Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy and Behavior, 2019, 101, 106296.	1.7	8
45	Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 796-805.	2.5	8
46	The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia, 2020, 61, e66-e70.	5.1	8
47	Clinical tolerance and toxicity of intravenous baclofen: A pilot study in a canine model. Journal of Pediatric Rehabilitation Medicine, 2011, 4, 89-98.	0.5	6
48	Pharmacokineticâ€Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbolâ€Đigit Modalities Test in Adult Healthy Volunteers. Journal of Clinical Pharmacology, 2016, 56, 714-722.	2.0	6
49	Chirally Pure Prodrugs and Their Converting Enzymes Lead to High Supersaturation and Rapid Transcellular Permeation of Benzodiazepines. Journal of Pharmaceutical Sciences, 2016, 105, 2365-2371.	3.3	6
50	Conversion of a soluble diazepam prodrug to supersaturated diazepam for rapid intranasal delivery: Kinetics and stability. Journal of Controlled Release, 2018, 289, 1-9.	9.9	6
51	Early Neurologic Recovery, Practice Pattern Variation, and the Risk of Endotracheal Intubation Following Established Status Epilepticus. Neurology, 2021, 96, e2372-e2386.	1.1	6
52	Relative Bioavailability, Metabolism??and Tolerability of??Rectally Administered Oxcarbazepine Suspension. Clinical Drug Investigation, 2007, 27, 243-250.	2.2	4
53	Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy. Journal of Inherited Metabolic Disease, 2020, 43, 564-573.	3.6	4
54	Intravenous and Intramuscular Allopregnanolone for Early Treatment of Status Epilepticus: Pharmacokinetics, Pharmacodynamics, and Safety in Dogs. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 104-113.	2.5	4

4

JAMES C CLOYD

#	Article	IF	CITATIONS
55	Synergistic chaperone activity of N-acetylcysteine and its metabolite L-cysteine in Gaucher disease. Molecular Genetics and Metabolism, 2020, 129, S84.	1.1	3
56	Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After Highâ€Dose Intravenous Administration in Young Children With Benzodiazepineâ€Refractory Status Epilepticus. Journal of Clinical Pharmacology, 2021, 61, 763-768.	2.0	3
57	Population Pharmacokinetic Analysis of Nâ€Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. Journal of Clinical Pharmacology, 2021, 61, 1638-1645.	2.0	3
58	Characterizing Baclofen Withdrawal: A National Survey of Physician Experience. Pediatric Neurology, 2021, 122, 106-109.	2.1	3
59	Translational and Clinical Pharmacology Considerations in Drug Repurposing for Xâ€linked Adrenoleukodystrophyâ€A Rare Peroxisomal Disorder. British Journal of Clinical Pharmacology, 2021, , .	2.4	2
60	Estimating the National Population of Hospitalized Chronic Baclofen Users: A Cross-Sectional Analysis of a Commercial Claims Database. Drugs - Real World Outcomes, 2022, 9, 307-314.	1.6	2
61	4512 Allopregnanolone Dose Finding for Status Epilepticus Treatment by Pharmacokinetic-Pharmacodynamic Modeling using Quantitative EEG in Dogs. Journal of Clinical and Translational Science, 2020, 4, 1-2.	0.6	1
62	Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults. Journal of Psychiatry and Brain Science, 2021, 6, .	0.5	1
63	A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clinical and Translational Science, 2021, 14, 1444-1451.	3.1	1